The indirect basal ganglia pathway in dopamine D2 receptor-deficient mice

Neuroscience

Volumn 99, Issue 4, 2000, Pages 643-650

  Murer, M G ^a   Dziewczapolski, G ^c   Salin, P ^d   Vila, M ^a   Tseng, K Y ^b   Ruberg, M ^a   Rubinstein, M ^e   Kelly, M A ^f   Grandy, D K ^f   Low, M J ^f   Hirsch, E ^a   Raisman Vozari, R ^a   Gershanik, O ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^d CNRS   (France)

^e INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Globus pallidus; Parkinson's disease; Striatum; Substantia nigra; Subthalamic nucleus

Indexed keywords

CYTOCHROME C OXIDASE; DOPAMINE 2 RECEPTOR; GLUTAMATE DECARBOXYLASE; MESSENGER RNA; SUBSTANCE P;

ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; GENE MUTATION; GLOBUS PALLIDUS; MOUSE; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; ELECTRON TRANSPORT COMPLEX IV; FEMALE; GENE EXPRESSION; GLOBUS PALLIDUS; GLUTAMATE DECARBOXYLASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOSTRIATUM; NEURAL PATHWAYS; NEURONS; PARKINSON DISEASE; PHENOTYPE; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SUBSTANCE P; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

EID: 0034706071     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00223-2     Document Type: Article

References (47)

1. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.-H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. natn. Acad. Sci. USA. 93:1996;1945-1949.
2. Aizman O., Brismar H., Uhlen P., Zettergren E., Levey A.I., Forssberg H., Greengard P., Aperia A. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat. Neurosci. 3:2000;226-230.
3. Aronin N., Chase K., DiFiglia M. Glutamic acid decarboxylase and enkephalin immunoreactive axon terminals in the rat neostriatum synapse with striatonigral neurons. Brain Res. 365:1986;151-158.
4. Asselin M.C., Soghomonian J.J., Cote P.Y., Parent A. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys. NeuroReport. 5:1994;2137-2140.
5. Baik J.-H., Picetti R., Dalardi A., Thirlet G., Dierich A., Depaulis A., Le Meur M., Borrelli E. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature. 377:1995;424-428.
6. Bisconte J.C., Fulcrand J., Marty R. Analyse radioautographique dans le systeme nerveux centrale par photometrie et cartographie combinees. C. r. Séanc. Soc. Biol. 161:1968;2178-2182.
7. Bolam J.P., Izzo P.N. The postsynaptic targets of substance P immunoreactive terminals in the rat neostriatum with particular reference to identified spiny striatonigral neurons. Expl Brain Res. 70:1988;361-377.
8. 125I]iodosulpride. Neuroscience. 20:1987;117-155.
9. Carlson J.H., Bergstrom D.A., Demo S.D., Walters J.R. Nigrostriatal lesion alters neurophysiological responses to selective and non-selective D1 and D2 dopamine agonists in rat globus pallidus. Synapse. 5:1990;83-93.
10. Chesselet M.-F., Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 19:1996;417-422.
11. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
12. Dickinson S.D., Sabeti J., Larson G.A., Giardina K., Rubinstein M., Kelly M.A., Grandy D.K., Low M.J., Gerhardt G.A., Zahniser N.R. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J. Neurochem. 72:1999;148-156.
13. Drago J., Gerfen C.R., Lachowicz J.E., Steiner H., Hollon T.R., Love P.E., Ooi G.T., Grinberg A., Lee E.J., Huang S.P., Bartlett P.F., Jose P.A., Sibley D.R., Westphal H. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. natn. Acad. Sci. USA. 91:1994;12,564-12,568.
14. Filion M., Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkey with MPTP-induced Parkinsonism. Brain Res. 547:1991;142-151.
15. Fontaine B., Sassoon D., Buckingham M., Changeux J.P. Detection of the nicotinic acetylcholine receptor subunit mRNA by in situ hybridization at the neuromuscular junction of 15-day-old chick striatal muscles. Eur. molec. Biol. Org. J. 7:1988;603-609.
16. Gerfen C.R., Engber T.M., Mathan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
17. Gerfen C.R., Keefe K.A., Gauda E.B. D1 and D2 dopamine receptor function in the striatum: coactivation of D1 and D2 dopamine receptors on separate populations of neurons results in potentiated immediate early gene responses in D1-containing neurons. J. Neurosci. 15:1995;8167-8176.
18. Hassani O.-K., Mouroux M., Féger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience. 72:1996;105-115.
19. Herrero M.-T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin M.R., Agid Y., Obeso J.A., Emson P.C. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 68:1995;1189-1198.
20. Herrero M.-T., Levy R., Ruberg M., Javoy-Agid F., Luquin M.R., Agid Y., Hirsch E.C., Obeso J.A. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in MPTP-treated monkeys and patients with Parkinson's disease. Adv. Neurol. 69:1996;209-216.
21. Johnson A.E., Coirini H., Kallstrom L., Wiesel F. Characterization of dopamine receptor binding sites in the subthalamic nucleus. NeuroReport. 5:1994;1836-1838.
22. Kawaguchi Y., Wilson C.J., Emson P.C. Projection subtypes of neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 10:1990;3421-3438.
23. Kelly M.A., Rubinstein M., Asa S.L., Zhang G., Saez C., Bunzow J.R., Allen R.G., Hnasko R., Ben-Jonathan N., Grandy D.K., Low M.J. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. 19:1997;103-113.
24. Kelly M.A., Rubinstein M., Phillips T.J., Lessov C.N., Burkhart-Kasch S., Zhang G., Bunzow J.R., Fang Y., Gerhardt G.A., Grandy D.K., Low M.J. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J. Neurosci. 18:1998;3470-3479.
25. 67 mRNA. Eur. J. Neurosci. 7:1995;1199-1209.
26. Levy R., Hazrati L.-N., Herrero M.-T., Vila M., Hassani O.-K., Mouroux M., Ruberg M., Asensi H., Agid Y., Féger J., Obeso J.A., Parent A., Hirsch E.C. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience. 76:1997;335-343.
27. Miller W.C., DeLong M.R. Parkinsonian symptomatology: an anatomical and physiological analysis. Ann. N. Y. Acad. Sci. 515:1988;287-302.
28. Mitchell I.J., Clark C.E., Boyce S., Robertson R.G., Peggs D., Sambrook M.A., Crossman A.R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-desoxyglucose in monkeys exposed to MPTP. Neuroscience. 32:1989;213-226.
29. Murer M.G., Riquelme L.A., Tseng K., Pazo J.H. Substantia nigra pars reticulata single unit activity in normal and 6-OHDA-lesioned rats: effects of intrastriatal apomorphine and subthalamic lesions. Synapse. 27:1997;278-293.
30. 125I]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions. NeuroReport. 10:1999;1501-1505.
31. Pan H.S., Walters J.R. Unilateral lesion of the nigrostriatal pathway decreases the firing rate and alters the firing pattern of globus pallidus neurons in the rat. Synapse. 2:1988;650-656.
32. Porter R.H.P., Greene J.G., Higgins D.S., Greenamyre J.T. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci. 14:1994;7192-7199.
33. Rubinstein M., Phillips T.J., Bunzow J.R., Falzone T.L., Dziewczapolski G., Zhang G., Fang Y., Larson J.L., McDougall J.A., Chester J.A., Saez C., Pugsley T.A., Gershanik O., Low M.J., Grandy D.K. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell. 90:1997;991-1001.
34. Ruskin D.N., Marshall J.F. D1 dopamine receptors influence Fos immunoreactivity in the globus pallidus and subthalamic nucleus of intact and nigrostriatal-lesioned rats. Brain Res. 703:1995;156-164.
35. Salin P., Dziewczapolski G., Gershanik O., Nieoullon A., Raisman-Vozari R. Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rats. Molec. Brain Res. 47:1997;311-321.
36. Smith Y., Bevan M.D., Shink E., Bolam J.P. Microcircuity of the direct and indirect pathways of the basal ganglia. Neuroscience. 86:1998;353-387.
37. Soghomonian J.J., Pedneault S., Audet G., Parent A. Increased glutamate decarboxylase mRNA levels in the striatum and pallidum of MPTP-treated primates. J. Neurosci. 14:1994;6256-6265.
38. Surmeier D.J., Song W.J., Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16:1996;6579-6591.
39. Vila M., Herrero M.-T., Levy R., Faucheux B., Ruberg M., Guillen J., Luquin M.R., Guridi J., Javoy-Agid F., Agid Y., Obeso J.A., Hirsch E.C. Consequences of nigrostriatal denervation on the GABAergic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology. 46:1996;802-809.
40. Vila M., Levy R., Herrero M.-T., Faucheux B., Obeso J.A., Agid Y., Hirsch E.C. Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study. Neuroscience. 71:1996;903-912.
41. Vila M., Levy R., Herrero M.-T., Ruberg M., Faucheux B., Obeso J.A., Agid Y., Hirsch E.C. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and non-human primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J. Neurosci. 17:1997;765-773.
42. Vila M., Marin C., Ruberg M., Jimenez A., Raisman-Vozari R., Agid Y., Tolosa E., Hirsch E.C. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in the basal ganglia. J. Neurochem. 73:1999;344-352.
43. Weiner D.M., Levey A.I., Sunahara R.K., Niznik H.B., O'Dowd B.F., Seeman P., Brann M. D1 and D2 dopamine receptor mRNA in rat brain. Proc. natn. Acad. Sci. USA. 88:1991;1859-1863.
44. Wichmann T., DeLong M.R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 6:1996;751-758.
45. Wong-Riley M.T.T. Changes in the visual system of monocularly sutured or enucleated cats demonstrable with cytochrome oxidase histochemistry. Brain Res. 171:1979;11-28.
46. Xu M., Moratalla R., Gold L.H., Hiroi N., Graybiel A.M., Tonegawa S. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell. 79:1994;729-742.
47. Yung K.K.L., Smith A.D., Levey A.I., Bolam J.P. Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat: evidence from dopamine receptor and neuropeptide immunostaining. Eur. J. Neurosci. 8:1996;861-869.